- Tak 799
-
-
2026-07-29
- CAS:229005-80-5
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
- TAK-779
-
- $38.00
-
2026-07-27
- CAS:229005-80-5
- Purity: 99.58%
- Supply Ability: 10g
|
| | Tak 799 Basic information |
| Product Name: | Tak 799 | | Synonyms: | 2H-Oyran-4-aminium, N-((4-(((6,7-dihydro-2-(4-methylphenyl)-5H-benzocyclohepten-8-yl)carbonyl)amino)phenyl)methyl)tetrahydro-N,N-dimethyl-;2H-Pyran-4-aminium, N,N-dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-, chloride;N,N-Dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-2H-pyran-4-aminium chloride;Tak 799;Takeda 779;TAK 799 ;TAK 779;TAK779;TAK 799;TAKEDA 779;N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium chloride | | CAS: | 229005-80-5 | | MF: | C33H39N2O2.Cl | | MW: | 531.136 | | EINECS: | | | Product Categories: | | | Mol File: | 229005-80-5.mol |  |
| | Tak 799 Chemical Properties |
| storage temp. | 2-8°C | | solubility | H2O: soluble3mg/mL, clear (warmed) | | form | powder | | color | white to beige | | Water Solubility | H2O: 3mg/mL, clear (warmed) | | InChIKey | VDALIBWXVQVFGZ-UHFFFAOYSA-N | | SMILES | C(=O)(NC1C=CC(=CC=1)C[N+](C)(C)C1CCOCC1)C1CCCC2C=CC(C3C=CC(C)=CC=3)=CC=2C=1.[Cl-] |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | Tak 799 Usage And Synthesis |
| Uses | TAK-779 has been used to inhibit CC chemokine ligand 5 (CCL5)– C-C chemokine receptor type 5 (CCR5) interaction in vitro in natural killer (NK) cytotoxicity assay. It has also been used as a blocker of CCR5 to study its effects and to evaluate the opening of the Panx-1 channels on peripheral blood mononuclear cells (PBMCs) isolated from human immunodeficiency virus (HIV)-infected individuals. | | Biochem/physiol Actions | TAK-779 is a potent, dual antagonist at chemokine receptors C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) with IC50 = 1.4 nM at CCR5 and 2.3 nM at CCR2. Antagonists of both CCR2 and CCR5 such as TAK-779 have been investigated for treatment of viruses, rheumatoid arthritis, multiple sclerosis, and cancer. CCR5 is particularly targeted for anti-HIV therapy, since HIV entry into cells requires chemokine coreceptors CCR5 and C-X-C motif chemokine receptor 4 (CXCR4). | | in vivo | TAK-779 (10 mg/kg per day, s.c.) significantly prolongs the allograft survival of the rat intestinal transplantation model. TAK-779 also decreases the number of CD4+ as well as CD8+ T cells in spleen, blood and recipient mesenteric lymph nodes (MLN)[2]. TAK-779 (150 μg per mouse, s.c.) supppresses the development of experimental autoimmune encephalomyelitis (EAE) in myelin oligodendrocyte glycoprotein (MOG)-immunized C57BL/6 mice. TAK-779 decreases the infiltration of CXCR3 and CCR5 bearing leukocytes into the spinal cord. TAK-779 does not alter myelin oligodendrocyte glycoprotein (MOG)-specific immune responses or affect the potential of MOG-specific T cells to transfer experimental autoimmune encephalomyelitis (EAE)[3]. | | IC 50 | MIP-1α-CCR5: 1 nM (IC50, in CHO/CCR5 cells); MIP-1β-CCR5: 1 nM (IC50, in CHO/CCR5 cells); RANTES-CCR5: 1.4 nM (IC50, in CHO/CCR5 cells); MCP-1-CCR2b: 27 nM (IC50, in CHO/CCR5 cells); R5 HIV-1 (Ba-L): 1.2 nM (EC50, in MAGI-CCR5 cells); R5 HIV-1 (KK): 1.6 nM (EC50, in PBMCs); R5 HIV-1 (HHA): 3.2 nM (EC50, in PBMCs); R5 HIV-1 (CTV): 3.5 nM (EC50, in PBMCs); R5 HIV-1 (Ba-L): 3.7 nM (EC50, in PBMCs); R5 HIV-1 (Ba-L): 5.7 nM (EC90, in MAGI-CCR5 cells); R5 HIV-1 (HHA): 7.5 nM (EC90, in PBMCs); R5 HIV-1 (Ba-L): 12.8 nM (EC90, in PBMCs); R5 HIV-1 (KK): 20.8 nM (EC90, in PBMCs); R5 HIV-1 (CTV): 27 nM (EC90, in PBMCs); mCXCR3: 369 nM (IC50, in PBMCs) | | storage | Store at -20°C |
| | Tak 799 Preparation Products And Raw materials |
|